Biocomposites commenced U.S. launch of STIMULAN® Rapid Cure 3cc synthetic calcium sulfate.
Designed specifically for smaller voids in reconstruction and trauma procedures in the foot and ankle, the new addition expands the company’s U.S. product portfolio for use in the presence of infection. STIMULAN is already used in over 50,000 cases every year globally, including 2,000 hospitals in the U.S.
Absorbable STIMULAN complements surgeons’ dead space management and can be used in both infected and non-infected bone sites. The 3cc size features a combination bead and bullet mat and can be mixed to meet any void size whatever the shape, accessibility or size constraints.
CEO Michael Harris said, “Our goal is to develop and provide products that can significantly improve patient outcomes and decrease hospital readmissions. We are proud of our highly skilled team of experts who developed STIMULAN and the new mini STIMULAN Rapid Cure 3cc pack. These are exciting times for the company as we continue to expand our U.S. product offering and increase our access to a larger segment of the U.S. market.”
Biocomposites commenced U.S. launch of STIMULAN® Rapid Cure 3cc synthetic calcium sulfate.
Designed specifically for smaller voids in reconstruction and trauma procedures in the foot and ankle, the new addition expands the company's U.S. product portfolio for use in the presence of infection. STIMULAN is already used in over 50,000 cases...
Biocomposites commenced U.S. launch of STIMULAN® Rapid Cure 3cc synthetic calcium sulfate.
Designed specifically for smaller voids in reconstruction and trauma procedures in the foot and ankle, the new addition expands the company’s U.S. product portfolio for use in the presence of infection. STIMULAN is already used in over 50,000 cases every year globally, including 2,000 hospitals in the U.S.
Absorbable STIMULAN complements surgeons’ dead space management and can be used in both infected and non-infected bone sites. The 3cc size features a combination bead and bullet mat and can be mixed to meet any void size whatever the shape, accessibility or size constraints.
CEO Michael Harris said, “Our goal is to develop and provide products that can significantly improve patient outcomes and decrease hospital readmissions. We are proud of our highly skilled team of experts who developed STIMULAN and the new mini STIMULAN Rapid Cure 3cc pack. These are exciting times for the company as we continue to expand our U.S. product offering and increase our access to a larger segment of the U.S. market.”
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
